141 related articles for article (PubMed ID: 24777311)
1. Invariant chain-MHC class II complexes: always odd and never invariant.
Cresswell P; Roche PA
Immunol Cell Biol; 2014 Jul; 92(6):471-2. PubMed ID: 24777311
[No Abstract] [Full Text] [Related]
2. The invariant chain p35 isoform promotes formation of nonameric complexes with MHC II molecules.
Cloutier M; Gauthier C; Fortin JS; Thibodeau J
Immunol Cell Biol; 2014 Jul; 92(6):553-6. PubMed ID: 24638068
[TBL] [Abstract][Full Text] [Related]
3. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.
Teyton L; O'Sullivan D; Dickson PW; Lotteau V; Sette A; Fink P; Peterson PA
Nature; 1990 Nov; 348(6296):39-44. PubMed ID: 2234057
[TBL] [Abstract][Full Text] [Related]
4. Type 1 diabetes associated HLA-DQ2 and DQ8 molecules are relatively resistant to HLA-DM mediated release of invariant chain-derived CLIP peptides.
Zhou Z; Reyes-Vargas E; Escobar H; Rudd B; Rockwood AL; Delgado JC; He X; Jensen PE
Eur J Immunol; 2016 Apr; 46(4):834-45. PubMed ID: 26707565
[TBL] [Abstract][Full Text] [Related]
5. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
6. HLA-DQA2 and HLA-DQB2 genes are specifically expressed in human Langerhans cells and encode a new HLA class II molecule.
Lenormand C; Bausinger H; Gross F; Signorino-Gelo F; Koch S; Peressin M; Fricker D; Cazenave JP; Bieber T; Hanau D; de la Salle H; Tourne S
J Immunol; 2012 Apr; 188(8):3903-11. PubMed ID: 22407913
[TBL] [Abstract][Full Text] [Related]
7. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.
Fujii S; Senju S; Chen YZ; Ando M; Matsushita S; Nishimura Y
Hum Immunol; 1998 Oct; 59(10):607-14. PubMed ID: 9757942
[TBL] [Abstract][Full Text] [Related]
8. NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ.
Karosiene E; Rasmussen M; Blicher T; Lund O; Buus S; Nielsen M
Immunogenetics; 2013 Oct; 65(10):711-24. PubMed ID: 23900783
[TBL] [Abstract][Full Text] [Related]
9. Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins.
Harris PE; Maffei A; Colovai AI; Kinne J; Tugulea S; Suciu-Foca N
Blood; 1996 Jun; 87(12):5104-12. PubMed ID: 8652823
[TBL] [Abstract][Full Text] [Related]
10. Class II MHC antigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain.
Hansson GK; Jonasson L; Holm J; Claesson-Welsh L
Clin Exp Immunol; 1986 May; 64(2):261-8. PubMed ID: 3527502
[TBL] [Abstract][Full Text] [Related]
11. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
12. MHC II and the endocytic pathway: regulation by invariant chain.
Landsverk OJ; Bakke O; Gregers TF
Scand J Immunol; 2009 Sep; 70(3):184-93. PubMed ID: 19703008
[TBL] [Abstract][Full Text] [Related]
13. MHC class II antigen-associated invariant chain on renal cell cancer may contribute to the anti-tumor immune response of the host.
Saito T; Kimura M; Kawasaki T; Sato S; Tomita Y
Cancer Lett; 1997 May; 115(1):121-7. PubMed ID: 9097987
[TBL] [Abstract][Full Text] [Related]
14. Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion.
Neumann J; Eis-Hübinger AM; Koch N
J Immunol; 2003 Sep; 171(6):3075-83. PubMed ID: 12960333
[TBL] [Abstract][Full Text] [Related]
15. Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments.
Moldenhauer G; Henne C; Karhausen J; Möller P
Immunology; 1999 Mar; 96(3):473-84. PubMed ID: 10233730
[TBL] [Abstract][Full Text] [Related]
16. Nonimmune human cells can express MHC class II antigens in the absence of invariant chain--an immunohistological study on normal and chronically inflamed small intestine.
Momburg F; Koretz K; Von Herbay A; Möller P
Clin Exp Immunol; 1988 Jun; 72(3):367-72. PubMed ID: 3048805
[TBL] [Abstract][Full Text] [Related]
17. MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo.
Cavalli G; Hayashi M; Jin Y; Yorgov D; Santorico SA; Holcomb C; Rastrou M; Erlich H; Tengesdal IW; Dagna L; Neff CP; Palmer BE; Spritz RA; Dinarello CA
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1363-8. PubMed ID: 26787888
[TBL] [Abstract][Full Text] [Related]
18. Complexes of two cohorts of CLIP peptides and HLA-DQ2 of the autoimmune DR3-DQ2 haplotype are poor substrates for HLA-DM.
Fallang LE; Roh S; Holm A; Bergseng E; Yoon T; Fleckenstein B; Bandyopadhyay A; Mellins ED; Sollid LM
J Immunol; 2008 Oct; 181(8):5451-5461. PubMed ID: 18832702
[TBL] [Abstract][Full Text] [Related]
19. MHC class II antigen expression in normal human epidermis.
Carr MM; McVittie E; Guy K; Gawkrodger DJ; Hunter JA
Immunology; 1986 Oct; 59(2):223-7. PubMed ID: 2429921
[TBL] [Abstract][Full Text] [Related]
20. The MHC class II beta chain cytoplasmic tail overcomes the invariant chain p35-encoded endoplasmic reticulum retention signal.
Khalil H; Brunet A; Saba I; Terra R; Sékaly RP; Thibodeau J
Int Immunol; 2003 Oct; 15(10):1249-63. PubMed ID: 13679394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
